Successful chemotherapy with modified FOLFIRINOX for pancreatic acinar cell carcinoma

被引：20

作者：

Hashimoto M. ^{[1
,2
]}

Hikichi T. ^{[3
]}

Suzuki T. ^{[1
]}

Tai M. ^{[1
]}

Ichii O. ^{[1
]}

Matsuhashi N. ^{[1
]}

Kita E. ^{[1
]}

Takahashi S. ^{[1
]}

Okubo Y. ^{[1
]}

Hakozaki H. ^{[4
]}

Ejiri Y. ^{[1
]}

Ohira H. ^{[2
]}

机构：

[1] Department of Gastroenterology, Fukushima Rosai Hospital, Iwaki

[2] Department of Gastroenterology, Fukushima Medical University School of Medicine, Fukushima

[3] Department of Endoscopy, Fukushima Medical University Hospital, 1 Hikarigaoka, Fukushima

[4] Department of Pathology, Fukushima Rosai Hospital, Iwaki

来源：

Clinical Journal of Gastroenterology | 2017年 / 10卷 / 6期

关键词：

Acinar cell carcinoma; Chemotherapy; Endoscopic ultrasound-guided fine needle aspiration; Modified FOLFIRINOX; Pancreatic cancer;

D O I：

10.1007/s12328-017-0785-5

中图分类号：

学科分类号：

摘要：

Abdominal ultrasonography revealed a pancreatic mass in a 67-year-old man with diabetes mellitus. Endoscopic ultrasound-guided fine needle aspiration led to the histological diagnosis of acinar cell carcinoma. The clinical stage was determined to be IVb based on findings of multiple metastatic lesions in the liver and lymph nodes, as well as splenic vein infiltration. Because the patient was not a surgical candidate, he underwent chemotherapy with modified FOLFIRINOX. In the absence of any severe adverse events, 12 courses of chemotherapy were delivered, resulting in marked shrinkage of both the primary and metastatic lesions. The outcome was judged to be a partial response, which was maintained even 9 months from the introduction of the chemotherapy. The results of this case suggest that modified FOLFIRINOX is safe and effective in the treatment of pancreatic acinar cell carcinoma. © 2017, Japanese Society of Gastroenterology.

引用

页码：564 / 569

页数：5

共 15 条

[1]

Ying J.E., Zhu L.M., Liu B.X., Developments in metastatic pancreatic cancer: is gemcitabine still the standard?, World J Gastroenterol, 18, pp. 736-745, (2012)

[2]

Stein S.M., James E.S., Deng Y., Et al., Final analysis of a phase II study of modified FOLFIRINOX in locally advanced and metastatic pancreatic cancer, Br J Cancer, 114, pp. 737-743, (2016)

[3]

Lowery M.A., Klimstra D.S., Shia J., Et al., Acinar cell carcinoma of the pancreas: new genetic and treatment insights into a rare malignancy, Oncologist, 16, pp. 1714-1720, (2011)

[4]

Webb J.N., Acinar cell neoplasms of the exocrine pancreas, J Clin Pathol, 30, pp. 103-112, (1977)

[5]

Schmidt C.M., Matos J.M., Bentrem D.J., Et al., Acinar cell carcinoma of the pancreas in the United States: prognostic factors and comparison to ductal adenocarcinoma, J Gastrointest Surg, 12, pp. 2078-2086, (2008)

[6]

Kitagami H., Kondo S., Hirano S., Et al., Acinar cell carcinoma of the pancreas: clinical analysis of 115 patients from Pancreatic Cancer Registry of Japan Pancreas Society, Pancreas, 35, pp. 42-46, (2007)

[7]

Seki Y., Okusaka T., Ikeda M., Et al., Four cases of pancreatic acinar cell carcinoma treated with gemcitabine or S-1 as a single agent, Jpn J Clin Oncol, 39, pp. 751-755, (2009)

[8]

Holen K.D., Klimstra D.S., Hummer A., Et al., Clinical characteristics and outcomes from an institutional series of acinar cell carcinoma of the pancreas and related tumors, J Clin Oncol, 20, pp. 4673-4678, (2002)

[9]

Lee J.L., Kim T.W., Chang H.M., Et al., Locally advanced acinar cell carcinoma of the pancreas successfully treated by capecitabine and concurrent radiotherapy: report of two cases, Pancreas, 27, pp. e18-e22, (2003)

[10]

Yoo C., Kim B.J., Kim K.P., Et al., Efficacy of chemotherapy in patients with unresectable or metastatic pancreatic acinar cell carcinoma: potentially improved efficacy with oxaliplatin-containing regimen, Cancer Res Treat., 49, pp. 759-765, (2017)

← 1 2 →